stockrow
Saturday 7 November 2026
Export NVCT’s income statement to Excel — free account
Nuvectis Pharma, Inc.
NVCT Healthcare Biotechnology
- EPS
- −131.9%
- Free cash flow
- −34.6%
Quarter to September 2026, against a year earlier
20.81
3.05
+17.17%
Follow NVCT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
9.92 | 1.68 | 2.27 | 2.38 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.53 | 3.08 | 4.01 | 4.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.65 | 1.08 | 0.54 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.86) | (0.19) | (0.28) | (0.18) | |
Cash per Share |
4.78 | 0.94 | 1.07 | 1.45 | |
Shareholders Equity per Share |
4.30 | 0.39 | 0.61 | 0.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.30 | 0.39 | 0.61 | 0.84 | |
Free Cash Flow |
(25.28) | (4.53) | (6.51) | (3.97) | |
Working Capital |
126.65 | 9.08 | 14.22 | 18.41 | |
Net Current Asset Value |
126.65 | 9.08 | 14.22 | 18.41 | |
| Other line items | |||||
Quick Ratio |
9.91 | 1.67 | 2.25 | 2.38 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.86) | (0.19) | (0.28) | (0.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
6.10 | 5.08 | 3.84 | 4.39 | |
Average Assets |
88.21 | 24.69 | 27.77 | 25.16 | |
Average Common Equity |
75.33 | 12.98 | 17.59 | 14.06 |
Columns are period end dates · fundamentals updated 6 Nov 2026